Harnessing Real World Data for Decentralised Trials: A Step-By-Step Regulatory Guide The integration of real-world data (RWD) and real-world evidence (RWE) in clinical trials represents a shift toward more practical and pragmatic approaches in the development of medical innovations. This tutorial will detail how stakeholders in digital health can navigate the FDA’s regulatory landscape to successfully utilize RWD, RWE, and digital endpoints in decentralised clinical trials. Understanding Real World Data (RWD) and Real World Evidence (RWE) Real World Data refers to the data obtained from various sources outside typical clinical trials. This includes information gathered from electronic health records, patient…

Balancing RCTs and RWE in Evidence Strategies for Digital Health Tools Balancing RCTs and RWE in Evidence Strategies for Digital Health Tools As the landscape of digital health evolves, demonstrating the safety and effectiveness of Software as a Medical Device (SaMD) has become increasingly complex. Regulatory bodies, primarily the U.S. Food and Drug Administration (FDA), are emphasizing the integration of Real-World Data (RWD) and Real-World Evidence (RWE) into clinical evaluation strategies. This tutorial aims to provide a step-by-step guide for regulatory, clinical, and quality leaders in the digital health sphere to effectively balance randomized controlled trials (RCTs) and RWE in…

Templates for RWE Sections in SaMD and Digital Therapeutic Submissions The integration of real-world data (RWD) and real-world evidence (RWE) into the regulatory submission process for Software as a Medical Device (SaMD) and digital therapeutics is becoming increasingly pivotal. The FDA, as part of its digital health strategy, recognizes the value and necessity of RWD and RWE in supporting regulatory submissions. This article serves as a step-by-step guide for regulatory professionals in the digital health sector, offering insights into effectively incorporating RWD and RWE into SaMD and digital therapeutic submissions. By understanding the regulatory framework and employing standardized templates, stakeholders…

Global Perspectives on Digital Evidence in EU MDR and HTA Assessments The increasing integration of digital health technologies, including Software as a Medical Device (SaMD), applications, and artificial intelligence (AI) solutions, has created an urgent need for regulatory frameworks that accommodate new sources of evidence. This comprehensive guide offers a detailed examination of real-world data (RWD), real-world evidence (RWE), and digital endpoints as they pertain to FDA submissions. It also positions EU Medical Device Regulation (MDR) and Health Technology Assessment (HTA) within this evolving landscape. By aligning our understanding with regulatory expectations, digital health innovators can effectively navigate the complex…

Engaging FDA Early on Digital Endpoints and RWE Plans for SaMD The advent of Software as a Medical Device (SaMD) has transformed the landscape of healthcare and the regulatory frameworks underpinning evaluation and approval processes. Engaging the FDA early in the development of digital endpoints and plans for Real-World Evidence (RWE) is pivotal for ensuring compliance, gaining insights, and refining your submission strategy. This comprehensive tutorial aims to guide digital health, regulatory, clinical, and quality professionals through the essential steps of navigating FDA regulations on RWD, RWE, and digital endpoints effectively. Understanding the Regulatory Frameworks The first step in engaging…